Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme

Gene Therapy

Volumn 7, Issue 21, 2000, Pages 1853-1858

  Rainov, N G ^a   Kramm, C M ^b   Banning, U ^b   Riemann, D ^a   Holzhausen, H J ^a   Heidecke, V ^a   Burger, K J ^c   Burkert, W ^a   Korholz D ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Novartis Pharma GmbH   (Germany)

Author keywords

Ganciclovir; Gene therapy; Glioblastoma; Peripheral blood mononuclear cells; Retrovirus; Thymidine kinase

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DEXAMETHASONE; FAS LIGAND; GAMMA INTERFERON; GANCICLOVIR; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; THYMIDINE KINASE; VIRUS VECTOR;

ADULT; AGED; ANIMAL CELL; ARTICLE; AUTOPSY; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOPHENOTYPING; INTERFERON PRODUCTION; LYMPHOCYTIC INFILTRATION; MALE; MITOSIS INDEX; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHARMACOGENOMICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR IMMUNOLOGY; TUMOR NECROSIS;

ANIMALIA; HERPES; PAPOVAVIRIDAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0033677346     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301311     Document Type: Article

References (35)

1. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
2. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
3. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
4. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges
5. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy
6. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
7. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
8. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
9. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
10. Gene therapy for malignant glioma patients
11. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy for previously untreated glioblastoma multiforme in adults
12. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo transduction with the herpes simplex thymidine kinase gene/ganciclovir system
13. Prodrug-activated gene therapy: Involvement of an immunological component in the 'bystander effect'
14. In vivo studies on the mechanism of the bystander effect
15. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
16. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
17. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses
18. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression
19. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice
20. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
21. MRI characteristics and histological changes in glioblastoma after gene therapy
22. Serum levels of interleukin-12 in patients with gastrointestinal cancer
23. Physiopathology of IL-12 in human solid neoplasms: Blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy
24. Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: Preliminary observations
25. Levels of soluble Fas ligand in myocarditis
26. Expression of the functional soluble form of human fas ligand in activated lymphocytes
27. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy
28. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells
29. Systemic activation of the immune system during ganciclovir treatment following intratumoral grafting of HSVtk retroviral vector producer cells in an adolescent ependymoma patient
30. The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness
31. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses
32. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy
33. Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF alpha IL-1beta and IL-8 mRNA levels. A comparison of monocyte isolation procedures
34. Generation of human T-cell responses to an HLA-A21-restricted peptide epitope derived from alpha-feto-protein
35. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals